Experimental Therapies for Relapsed Myeloma

Dan Vogl, MD, discusses current clinical trials in drug therapy for relapsed and refractory myeloma, including carfilzomib, pomalidomide, ibrutinib, the monoclonal antibodies, the HDAC inhibitors and the oral proteosome inhibitors, and reviews the many clinical trials ongoing at Penn Medicine in the field.